What Syntekabio does

Syntekabio is a South Korea-based AI drug discovery company listed on KOSDAQ (ticker: 226330), founded in 2009 and headquartered in Daejeon. The company operates an integrated AI drug discovery platform across three therapeutic modalities: small molecules (SM-ARS), antibodies (AB-ARS), and neoantigens/cancer vaccines (NEO-ARS), underpinned by two core AI engines — DEEPMATCHER (a language model for protein-compound interaction prediction) and LM-VS (language model-based virtual screening across 10 billion compounds). The platform is powered by a proprietary 15MW AI Bio Supercomputing (ABS) Data Center in Daejeon featuring 5,000+ GPU clusters and a patented termite-mound-inspired natural convection cooling system achieving PUE of 1.13.

The company monetizes through multiple channels: SaaS subscriptions for LM-VS at $20,000 per target protein (delivering top 200 candidates within 3 weeks), fee-for-service custom project collaborations, pre-validated AI Asset Programs (covering targets such as BCL2, BTK, CDK2/4/6, KRAS, FGFR1/2/3), PaaS subscriptions planned for H2 2025, and newly launched data center IDC colocation services. Customers include global pharma and biotech firms such as Memorial Sloan Kettering Cancer Center, MetaVia, Pragma Bio, OCMS Bio, and Rudacure, alongside an unnamed Nasdaq-listed TPD company and the world's largest animal health company. H1 2025 disclosed revenue was KRW 1.2 billion (~USD 870K), with over KRW 1.0 billion generated from the DeepMatcher platform alone. GTM operates through direct B2B sales, supplemented by product-led self-serve access via the LM-VS SaaS platform launched for global markets in 2025, and academic publication-driven thought leadership.

Name

Syntekabio

Legal name

Syntekabio, Inc.

Website

https://syntekabio.com

Company type

Public

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Syntekabio is a KOSDAQ-listed South Korean AI drug discovery company offering an integrated platform spanning small molecules, antibodies, and neoantigens, powered by proprietary language models and a 15MW AI Bio Supercomputing Center, serving global pharma and biotech clients.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• AI drug discovery
• Drug development platform
• Pharmaceutical AI
• Biotech software
• Computational biology

Headquarters

HQ city

Daejeon

HQ country

South Korea

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. AI Drug Discovery Platform Services: Revenue generated from providing access to AI drug discovery platforms including DeepMatcher and LM-VS. In H1 2025, over KRW 1.0 billion was generated from the DeepMatcher platform alone, demonstrating commercial viability of the technology. The company launched LM-VS as a SaaS product for global markets in H1 2025, with an upgraded PaaS version planned for H2 2025.
2. Data Center Colocation / IDC Leasing: Revenue from leasing colocation services at the proprietary AI Bio Supercomputing (ABSC) data center. Syntekabio has signed contracts with two clients with further negotiations ongoing. Expected annual recurring revenue of KRW 2 billion with potential to reach KRW 3 billion at full capacity.
3. System Integration (SI) Services: Newly established SI division generating revenue from services such as eCommerce development and website development projects. First contract valued at approximately KRW 100 million secured in Q2 2025, with ongoing contract wins in Q3.
4. AI-Driven Asset Programs (Pre-validated Drug Candidate Packages): Revenue from selling pre-validated, AI-screened drug candidate packages (Asset Program) to pharmaceutical companies for immediate research use. Candidates include targets such as BCL2, BTK, CDK2/4/6, FGFR1/2/3, KRAS, and others. Packages include target-specific ELISA and expression data in standardized format.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Syntekabio is an AI-driven drug discovery company that develops and operates proprietary software platforms (SM-ARS, AB-ARS, NEO-ARS, DEEPMATCHER, LM-VS) used by pharmaceutical and biotechnology companies to identify and optimize drug candidates. The company also operates a 15MW AI Bio Supercomputing (ABS) Data Center that supports its drug discovery workloads and provides colocation services, alongside asset programs that progress selected therapeutic candidates through development.

Product overview

Syntekabio is an AI-powered drug discovery company offering a platform-plus-modules architecture. The core AI Drug Discovery Platform consists of five interconnected products: SM-ARS® for small molecule drug discovery, AB-ARS® for antibody candidate design, NEO-ARS® for neoantigen discovery and cancer vaccine design, DEEPMATCHER® as the underlying AI language model for protein-compound interaction prediction, and LM-VS™ for large-scale virtual screening of 10 billion compounds. These platforms are powered by the company's proprietary AI Bio Supercomputing (ABS) Data Center in Daejeon. The Asset Program provides pre-validated, ready-to-use drug candidate packages as an add-on offering. The company also operates data center colocation services and system integration divisions.

Differentiator

Problem solved

Functional benefit

Brands

• DeepMatcher®: AI-driven drug candidate discovery platform for protein-compound interaction prediction
• LM-VS™
• SM-ARS®
• AB-ARS®
• NEO-ARS®
• ABSC (AI Bio Supercomputing Center)
• STB Cloud

Products and services

• SM-ARS (Small Molecule AI-driven Research Suite)
• AB-ARS (Antibody AI-driven Research Suite)
• NEO-ARS (New Entity Optimization AI-driven Research Suite) AI platform focused on novel entity optimization for new drug candidates, including multi-parameter property prediction and candidate prioritization.
• DEEPMATCHER AI-based molecular matching and screening platform that pairs compounds with biological targets to accelerate early-stage drug discovery.
• LM-VS (Language Model - Virtual Screening) Language model-based virtual screening tool that uses natural language processing and deep learning to predict molecular activity and properties.
• Asset Program Therapeutic asset program in which Syntekabio identifies and advances selected drug candidates through preclinical development using its AI platforms.
• AI Bio Supercomputing (ABS) Data Center 15MW-class AI-focused data center providing high-performance computing infrastructure and colocation services for AI workloads in life sciences.

Quantifiable outcome

• 3x faster drug discovery timelines
• +7 more outcomes

Named customers6 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability8 records

Feature7 records

Partnerships

Seven partnerships are on record, tiered core, major and standard.

• MetaVia Inc.coreStrategic or Co-development PartnerOngoing AI collaboration using Syntekabio's DeepMatcher platform to confirm therapeutic targets for MetaVia's oral GPR119 agonist vanoglipel (DA-1241). AI modeling identified inflammatory diseases, cardiometabolic disorders, and cancer as top predicted therapeutic areas, supporting development for MASH and type 2 diabetes. Phase 2a clinical data showed direct hepatic activity, improved glucose metabolism, and favorable safety profile in 109 patients over 16 weeks. Collaboration continues to explore additional indications and optimize the drug's therapeutic profile.
• Memorial Sloan Kettering Cancer Center (MSK)coreStrategic or Co-development PartnerExpanded ongoing collaboration with MSK to include research on a second oncology target. Syntekabio utilizes its AI platforms LM-VS and DeepMatcher to perform virtual screening and deliver candidate compounds for validation and testing at MSK's laboratories.
• Pragma BiomajorStrategic or Co-development PartnerKRW 4.5 billion deal with US-based Pragma Bio to discover targets related to inflammatory bowel disease (IBD) and conduct preclinical research. Represents a significant international contract for Syntekabio.
• OCMS BiomajorStrategic or Co-development PartnerUS-based antibody discovery and engineering firm conducting antibody optimization and efficacy validation for undisclosed targets with Syntekabio. The two companies co-launched an AI-based one-shot antibody screening platform, expanding Syntekabio's global research network.
• RudacurestandardStrategic or Co-development PartnerKorean biopharma R&D firm collaborating with Syntekabio for anti-cancer candidate identification using the company's AI drug discovery platforms.
• Undisclosed U.S. Nasdaq-listed TPD CompanystandardStrategic or Co-development PartnerU.S. Nasdaq-listed company specializing in Target Protein Degradation (TPD) has entered into first and second stage compound discovery contracts with Syntekabio.
• Undisclosed World's Largest Animal Health CompanystandardStrategic or Co-development PartnerCo-development of veterinary therapeutics with the world's largest animal health company using Syntekabio's proprietary AI platforms.

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Schrödinger: Physics-based computational chemistry and AI platform for drug discovery, including virtual screening and molecular dynamics. Syntekabio's 3D docking and flexible-mold approach in DeepMatcher competes directly with Schrödinger's LiveDesign and Glide platforms.
• Atomwise: AI-driven small molecule discovery platform using convolutional neural networks for virtual screening across massive compound libraries. Directly comparable to LM-VS in targeting ultra-fast, large-scale hit identification for pharma partners.
• XtalPi: AI and quantum physics-based drug discovery company combining computation with laboratory automation. Operates similar platform-plus-services model with major pharma collaborations, comparable to Syntekabio's platform offerings and partnership pipeline.
• BenevolentAI: AI drug discovery company applying knowledge graphs and machine learning to identify novel targets and drug candidates. Comparable in combining biomedical data, AI models, and pharma collaborations to accelerate discovery.
• Insilico Medicine: AI-driven drug discovery company offering end-to-end platforms for target identification, generative chemistry, and clinical prediction. Directly comparable to Syntekabio's DeepMatcher and LM-VS offerings in applying AI/ML to small molecule discovery, with similar focus on pharma collaborations.
• Recursion Pharmaceuticals: AI-first biotech combining high-throughput experimentation with machine learning for drug discovery across small molecules and biologics. Comparable business model of platform-plus-pipeline with a strong supercomputing/data infrastructure component similar to Syntekabio's ABSC.

Regional players

• Deargen: Korean AI biotech focused on target identification and drug repurposing using deep learning on omics data. Comparable in applying AI/ML to early-stage drug discovery and operating from the Korean ecosystem with similar investor profiles.
• Standigm: Korean AI drug discovery company offering end-to-end platforms for target identification, lead generation, and drug repurposing. Closest regional peer given shared Korean ecosystem, comparable platform approach, and overlapping customer base in domestic pharma.

Emerging players

• Iambic Therapeutics: AI-driven drug discovery platform using novel neural network architectures for predicting molecular properties and designing therapeutics. Comparable as a smaller, AI-native platform player pursuing pharma partnerships and SaaS-style access to discovery tools.
• Pharos iBio: Korean AI-based drug discovery company using proprietary platforms for novel target identification and small molecule development. Comparable in applying AI to reduce drug discovery timelines and costs, though at smaller scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@syntekabio8945
• LinkedInlinkedin.com/company/syntekabio
• Xx.com/syntekabio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syntekabio